Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Sana, CAMP4 ditch clinical-stage assets for preclinical hopefuls
Sana, CAMP4 and Crinetics have used the third quarter to refocus their pipelines on the most promising candidates.
James Waldron
Nov 7, 2025 8:13am
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
AstraZeneca drops MASH drug over disappointing data
Nov 6, 2025 5:21am
Novo drops oncology ambitions, early-stage MASH prospects
Nov 5, 2025 7:21am
Amgen halts gastric cancer trial after subpar efficacy analysis
Nov 5, 2025 4:35am
FDA rejects Biohaven approval request, triggering cost cutting
Nov 5, 2025 4:02am
